Faruqi and Faruqui, LLP Logo
Share this page

Medgenics, Inc. (MDGN)



Faruqi & Faruqi, LLP Launches An Investigation Against Medgenics, Inc. (MDGN) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medgenics, Inc. (“Medgenics” or the “Company”) (NYSE: MDGN) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for an amendment to the Medgenics, Inc. Stock Incentive Plan.

Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on March 11, 2014, the Board of Directors recommends that Medgenics’s shareholders vote to approve the issuance of shares of the common stock by 2,000,000 under the Stock Incentive Plan.  The issuance of these shares could have a substantial dilutive effect on the shares of Medgenics common stock.

If you own common stock in Medgenics and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Request Information

Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.

  • Company:
    Medgenics, Inc. (MDGN)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

MergerInfo Request
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 03/14/2014

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.